1. World Health Organization. Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections. Overview and Estimates. Geneva: WHO, 2001.
2. Centers for Disease Control and Prevention. Sexually Transmitted Diseases. Treatment Guidelines 2006. MMWR 2006; 55 (N RR–11).
3. European Guideline for the Management of Sexually Transmitted Infections. Int J STD AIDS 2003; 12 (Suppl. 3).
4. International Handbook of Chlamydia (2nd Edition). Ed. Moss T.R. Euromed Communications Ltd, UK, 2006.
5. Paavonen J, Eggert-Kruse W. Chlamydia trachomatis: impact on human reproduction. Hum Reprod 1999; 5: 433–47.
6. Cohen DA, Nsuami M, Martin DH, Farley TA. Repeated school-based screening for sexually transmitted diseases: a feasible strategy for reaching adolescents. Pediatrics 1999; 104: 1281–5.
7. Pacey AA, Eley A. Chlamydia trachomatis and male fertility. Hum Fertil (Camb) 2004; 7: 271–6.
8. Тихомиров А.Л., Сарсания С.И. Современные принципы профилактики и лечения воспалительных заболеваний женских половых органов в оперативной и неоперативной гинекологии. Методические рекомендации. М., 2005.
9. Patel DR. Management of pelvic inflammatory disease in adolescents. Indian J Pediatr 2004; 71: 845–47.
10. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2007; 30: 213–321.
11. Аковбян В.А. Азитромицин (сумамед) как препарат первого выбора при лечении урогенитального хламидиоза. Клин. дерматол. и венерол. 2006; 1: 18–23.
12. Хрянин А.А., Королев М.А., Гришина Н.А. Рациональная антибактериальная и неспецифическая терапия инфекций, передаваемых половым путем: фармакологические и иммунологические обоснования. Клин. дерматол. и венерол. 2006; 2: 103–8.
13. Доказательная медицина. М.: Медиа Сфера, 2002; 1: 968–77.
14. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis 2002; 29 (9): 497–502.
15. Khaki P, Bhalla P, Sharma A, Kumar V. Correlation between In vitro susceptibility and treatment outcome with azithromycin in gonorrhoea: a prospective study. Indian J Med Microbiol 2007; 25 (4): 354–7.
16. Ross JD, Cronje HS, Paszkowski T et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex Transm Inf 2006; 82: 446–51.
17. Judlin P. Current concepts in managing pelvic inflammatory disease. Curr Opin Infect Dis 2010; 23: 83–7.
18. Haggerty CL, Ness RB.Diagnosis and treatment of pelvic inflammatory disease. Womens Health (Lond Engl). 2008; 4 (4): 383–97.
19. Ушкалова Е.А. Применение азитромицина для профилактики и лечения воспалительных заболеваний органов малого таза и урогенитального хламидиоза. http://medi.ru/DOC/1475183.htm.
20. Colin DB et al. An open-label, randomised, comparative study of intravenous and oral azithromycin alone or with metronidasole vs doxycicline + cefoxitin + metronidasol + probenecid for the treatment of acute pelvic inflammatory disease. ICMAS-KO 5, 2000.
21. Bevan CD, Ridgway GL, Rotermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003; 31 (1): 45–54.